You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,994,840


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,994,840
Title:Kit for radiolabeling ligands with yttrium-90
Abstract: Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful in bringing radioimmunotherapy to the hospital and outpatient setting for the treatment of cancer.
Inventor(s): Chinn; Paul (Carlsbad, CA)
Assignee: Biogen IDEC Inc. (Cambridge, MA)
Application Number:09/628,186
Patent Claims:1. A method for radiolabeling a chelator-conjugated antibody or antibody fragment with a therapeutic radioisotope for administration to a patient comprising (i) mixing the chelator-conjugated antibody or antibody fragment with a solution comprising the therapeutic radioisotope or salt thereof, and (ii) incubating the mixture for a sufficient amount of time under amiable conditions such that a radiolabeled antibody or antibody fragment is produced having sufficient radioincorporation, sufficient immunoreactivity, and a specific activity of at least about 5 mCi/mg, such that the radiolabeled antibody or antibody fragment may be administered directly to the patient without further purification of the radiolabeled antibody or antibody fragment from unincorporated radioisotope.

2. The method of claim 1, wherein said therapeutic radioisotope is selected from the group consisting of alpha and beta emitters.

3. The method of claim 2, wherein said therapeutic radioisotope is a beta emitter.

4. The method of claim 3, wherein said beta emitter is .sup.90Y.

5. The method of claim 4, wherein said sufficient incubation time is about ten minutes.

6. The method of claim 4, wherein said sufficient incubation time is less than about eight minutes.

7. The method of claim 6, wherein said sufficient incubation time is between about 30 seconds to about five minutes.

8. The method of claim 6, wherein said sufficient incubation time is about three minutes.

9. The method of claim 6, wherein said sufficient incubation time is about five minutes.

10. The method of claim 4, wherein the specific activity of the radiolabeled antibody or antibody fragment is over 10 mCi/mg.

11. The method of claim 10, wherein the specific activity of the radiolabeled antibody or antibody fragment is at least 15 mCi/mg.

12. The method of claim 11, wherein the specific activity of the radiolabeled antibody or antibody fragment is about 20 mCi/mg.

13. The method of claim 4, wherein the antibody or antibody fragment is a therapeutic antibody or antibody fragment.

14. The method of claim 13, wherein the antibody fragment is selected from the group consisting of Fab, F(ab').sub.2, and Fv fragments.

15. The method of claim 13, wherein the antibody or antibody fragment binds specifically to CD20.

16. The method of claim 15, wherein the antibody is 2B8.

17. The method of claim 16, wherein the chelator is MX-DTPA.

18. The method of claim 17, wherein a level of radioincorporation greater than 95% is achieved.

19. The method of claim 18, wherein a level of radioincorporation greater than 96% is achieved.

20. The method of claim 19 wherein a level of radioincorporation of from 96.3 to 99.5% is achieved.

21. The method of claim 1, wherein a level of radioincorporation of greater than 95% is achieved.

22. The method of claim 1, wherein said chelator is a bifunctional chelator selected from the group consisting of MX-DTPA, phenyl-DTPA, benzyl-DTPA, CHX-DTPA, DOTA and derivatives thereof.

23. The method of claim 22, wherein said chelator is MX-DTPA.

24. The method of claim 23, wherein the ratio of chelator to antibody or antibody fragment ranges from 11/2 to 1.

25. The method of claim 1, wherein said amiable conditions refer to acceptable temperature, pH and buffer conditions.

26. The method of claim 25, wherein said acceptable temperature ranges from about 25.degree. C. to about 50.degree. C.

27. The method of claim 26, wherein said acceptable temperature ranges from about 25.degree. C. to about 43.degree. C.

28. The method of claim 25, wherein said acceptable pH ranges from about 3 to about 6.

29. The method of claim 28, wherein said acceptable pH is about 4.2.

30. The method of claim 25, wherein said acceptable buffer is an acetate buffer.

31. The method of claim 30, wherein said buffer is sodium acetate is at a concentration of between about 10 and about 1000 mM.

32. The method of claim 25, where said acceptable buffer includes a benign radioprotectant.

33. The method of claim 32, wherein said benign radioprotectant is ascorbate.

34. The method of claim 1, wherein said immunoreactivity is at least 70%.

35. The method of claim 1, wherein a level of radioincorporation of at least about 96% is achieved.

36. The method of claim 1, wherein a level of radioincorporation of at least about 97% is achieved.

37. The method of claim 1, wherein a level of radioincorporation of at least about 98% is achieved.

38. The method of claim 1, wherein a level of radioincorporation of at least about 99% is achieved.

39. The method of claim 1, wherein the antibody fragment is selected from the group consisting of Fab, F(ab').sub.2, and Fv fragments.

40. The method of claim 1, wherein the immunoreactivity is at least 50%.

41. The method of claim 1, wherein the immunoreactivity is at least 80%.

42. The method of claim 1, wherein a level of radioincorporation greater than 96% is achieved.

43. The method of claim 1, wherein a level of radioincorporation of from 96.3 to 99.5% is achieved.

International Patent Family for US Patent 6,994,840

Country Patent Number Estimated Expiration
South Africa 200106945 ⤷  Try a Trial
Yugoslavia 61701 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 0052031 ⤷  Try a Trial
United States of America 7618613 ⤷  Try a Trial
United States of America 7229620 ⤷  Try a Trial
United States of America 2007297978 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.